TECHNOLOGY PLATFORMS

The glycoconjugate pro-drug delivery platform consists of new compositions of matter re-engineered from existing pharmaceutical agents by proprietary chemical bonding to transport molecules. 

 

The chemical modification enables blood brain barrier transport of drugs that would not otherwise reach efficacious levels in the brain without the risk of systemic side-effects. 

 

The lead drug candidate in this platform is IPX-750 for the treatment of Parkinson’s disease.

Learn more:

  • Facebook Social Icon
  • Twitter Social Icon
GLYCON PHARMA
CONTACT:  MIKE ALLEN
TEL:  (205) 405-4114
EMAIL:
mallen@glyconpharma.com

© 2018 by Glycon Pharma.            Powered by Bright Idea Web Design.